Highlights

  • Starpharma shares rose 2.84% to AUD 0.72 on 29 April 2026 following its Q3 FY26 update.
  • FDA alignment confirmed for DEP HER2 first-in-human Phase 1 study.
  • Clinical trial preparations for DEP HER2 are progressing, with site selection completed.
  • Strategic partnerships advanced, including engagement at global industry conferences.
  • Data from collaboration with Genentech published, supporting DEP platform potential.
  • Cash balance stood at AUD 14.1 million as at 31 March 2026.
  • Net operating cash outflow for the quarter was AUD 3.9 million.

Starpharma Holdings Ltd (ASX:SPL) shares increased by 2.84% to AUD 0.72 during the morning session on 29 April 2026, following the release of its Quarterly Activities Report and Appendix 4C for the period ended 31 March 2026. The stock has recorded a significant rise of over 700% over the past year, with the latest movement coinciding with updates on regulatory progress, pipeline development, and ongoing strategic initiatives.

The company’s latest update reflects continued advancement across its clinical and Partnership programs, alongside progress in preparing for upcoming clinical milestones. Developments related to regulatory alignment and internal pipeline progression appear to have contributed to the market’s response.

Company Overview

Starpharma is a biotechnology company focused on developing and commercialising dendrimer-based technologies. With over two decades of experience, the company’s work centres on applying its DEP (dendrimer enhanced product) platform to improve the delivery, efficacy, and tolerability of therapeutic compounds.

Dendrimers are nanoscale, synthetically engineered molecules with defined structures and properties such as high branching and water solubility. These characteristics support their application in pharmaceutical development, particularly in targeted drug delivery.

The company’s portfolio includes clinical-stage DEP Assets, preclinical radiopharmaceutical programs, research collaborations, and marketed over-the-counter products such as Viraleze and VivaGel BV. Starpharma’s strategy combines internal development with external partnerships and licensing opportunities.

Regulatory Milestone for DEP HER2

A key development during the quarter was progress related to Starpharma’s DEP HER2 radiotherapeutic program. In April 2026, the company confirmed alignment with the United States Food and Drug Administration (FDA) following a Type C meeting.

The FDA provided feedback supporting the proposed clinical development strategy and study design for the DEP HER2 first-in-human Phase 1 trial. This outcome indicates that the preclinical data and planned clinical approach are considered adequate to support future studies under an Investigational New Drug (IND) framework.

DEP HER2 is designed as a HER2-targeted dendrimer conjugate carrying a lutetium-177 radionuclide payload. The therapy is being developed for patients with advanced HER2-expressing cancers who have previously undergone HER2-targeted treatments.

The regulatory feedback also highlighted that this patient group represents a significant unmet medical need, reinforcing the rationale behind the program. The alignment provides clarity as the asset transitions from preclinical stages toward clinical evaluation.

Clinical Trial Preparations Progress

Starpharma reported that preparations for the DEP HER2 first-in-human Phase 1 study are progressing in line with expectations. Clinical site selection has been completed, and further activities are underway to support trial initiation.

These include radiopharmacy preparations, onboarding of clinical sites, and completion of ethics and regulatory approvals. The company continues to target commencement of the trial in Europe during the second half of calendar year 2026.

Alongside DEP HER2, Starpharma is continuing to assess additional therapeutic opportunities and modalities where its dendrimer platform could be applied. This approach reflects ongoing efforts to expand the company’s internal pipeline.

Strategic Partnerships and Platform Validation

During Q3 FY26, Starpharma continued advancing its strategic Partnership programs. The company reported that existing collaborations are progressing according to development plans, with a focus on achieving future milestones.

The company also engaged with potential partners at industry events including JP Morgan in January and BIO-Europe in March. These interactions were centred on the Star Navigator program, which is designed to facilitate collaboration by allowing partners to explore dendrimer drug conjugates and evaluate compatibility with the DEP platform.

In April, data from an early-stage research collaboration with Genentech was published in the Journal of Pharmaceutical Sciences. The study examined the use of DEP dendrimer technology in enhancing SMARCA2-targeting PROTACs within a non-small cell lung cancer model.

According to the findings, conjugating PROTACs with the DEP platform resulted in sustained tumour exposure, durable tumour control, and improved tolerability. These outcomes support the broader applicability of the platform across emerging therapeutic approaches.

Commercial Activities and Product Performance

Starpharma continued to support the commercialisation of its marketed products during the quarter. Sales of Viraleze through online channels increased by approximately 65% year-to-date compared to the prior corresponding period.

The company also maintained support for its global partners associated with Viraleze and VivaGel BV, including E&N, ITROM, and Aspen. It noted ongoing commercial interest in these products, particularly VivaGel BV in the European market.

Efforts remain focused on converting Partnership opportunities into broader distribution arrangements, which could contribute to Revenue growth over time.

Financial Position and Cash Flow

As at 31 March 2026, Starpharma reported a cash balance of AUD 14.1 million. The company indicated that year-to-date net operating cash flows reflect a break-even position.

For the quarter, net operating cash outflows were AUD 3.9 million. Receipts totalled AUD 0.9 million, comprising Research and Development income and product sales.

Operating expenses included:

  • Research and Development costs of AUD 2.0 million
  • Staffing costs of AUD 2.1 million, including AUD 267,000 paid to directors

Additional related party transactions included AUD 21,339 paid to CBE Pure Solutions.

From a Cash Flow perspective:

  • Net cash from Operating Activities was negative AUD 3.9 million year-to-date
  • Investing activities recorded a net outflow of AUD 0.26 million
  • Financing activities recorded a net outflow of AUD 1.05 million

Total available funding at quarter-end, including unused financing facilities, stood at approximately AUD 14.38 million. Based on current cash usage, the company estimates around 3.7 quarters of funding available.

Starpharma also indicated expectations for lower net operating cash outflows in the fourth quarter and noted that it anticipates receiving an R&D tax incentive payment in early FY27.

Investor Engagement and Market Positioning

During the quarter, CEO Cheryl Maley presented at the Ignite Investment Summit in Hong Kong in April 2026. The presentation focused on Starpharma’s DEP platform, its application in oncology, and the company’s strategy for value creation.

The company highlighted multiple pathways to growth, including partnerships, licensing agreements, internal development programs, and its Star Navigator initiative. These efforts are aimed at advancing its technology while engaging with potential collaborators and investors.

What This Means for Investors?

Starpharma’s latest quarterly update reflects continued progress across regulatory, clinical, and Partnership activities. The confirmation of FDA alignment for the DEP HER2 program represents a notable milestone as the company prepares to enter clinical stages.

At the same time, advancements in strategic collaborations, publication of research data, and ongoing commercial activity provide additional context around the company’s broader development strategy.

The share price movement on 29 April 2026 appears to align with these developments, particularly the regulatory clarity and clinical progress outlined in the update. Investors may continue to monitor upcoming milestones, including the initiation of the Phase 1 study and further Partnership developments.